ETON PHARMACEUTCIALS INC (ETON)
Health Care · Specialty Pharmaceuticals · NASDAQ
Eton Pharmaceuticals is a specialty drug company dedicated to acquiring and commercializing a diverse portfolio of therapies for rare diseases.
What ETON PHARMACEUTCIALS INC does
Eton Pharmaceuticals is an innovative pharmaceutical company focused on the development and commercialization of treatments for rare diseases. The company maintains a portfolio of commercial rare disease products and several candidates in late-stage development. Its business model involves acquiring and commercializing specialty pharmaceutical assets.
Themes: rare diseases, orphan drugs, pharmaceutical commercialization
Fundamentals
- Price$64.43 as of 2026-08-24 close
- Market cap$1.8B as of 2026-08-24
- 1-year return+272.4% 2025-08-22 close $17.30 → 2026-08-24 close $64.43
- P/En/a negative earnings
- Net margin-1.7% as of 2026-08-26
- Gross margin+54.8% as of 2026-08-26
- ROE-5.7% as of 2026-08-26
- Debt / equity1.00 as of 2026-08-26
- Revenue growth (YoY)+79.9% as of 2026-08-26
- Revenue CAGR (3y)+55.5% SEC XBRL
- Beta0.89 as of 2026-08-26
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How ETON compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-26
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-26
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-26
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-26
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ETON PHARMACEUTCIALS INC looks technically
ETON PHARMACEUTCIALS INC (ETON) is trading 146.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 104 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 44, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 74, in overbought territory (above 70). MACD, a trend-momentum gauge, turned bullish about 7 trading days ago (its momentum flipped positive). It just made a new 20-day high, pushing above its recent trading range. It is 2.9% below its all-time high.
Trend
8
| Distance from the 200-day | it is trading 146.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +146.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $42.68 | $42.68 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $26.14 | $26.14 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 13 calendar days ago — the swings before that are what the structure reading is measured on | 13 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes below 40.61. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 104 trading days ago — a "golden cross", a bullish long-term signal | 104 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 44, with buyers in control | 44.1 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 74, in overbought territory (above 70) | 74.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($40.61 to $66.37) — its "stochastic" reading is 92 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 92.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 7 trading days ago (its momentum flipped positive) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $66.37 | $66.37 |
|---|---|---|
| From the 52-week high | it is 2.9% below its 52-week high (its highest price of the past year) | -2.9% |
| Above the 52-week low | it is 351.5% above its 52-week low (its lowest price of the past year) | +351.5% |
| Below the 52-week high | it is 2.9% below its highest point of the past year | 2.9% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $66.37 (set on 2026-08-24) | $66.37 |
| Given back of the 52-week move | over the past year its closes ranged ($14.35 to $64.43), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $31.88 to $33.48. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 2.9% below its all-time high | -2.9% |
| Nearest price level | it is trading 69.0% above a support level at $20.01 — a price it turned at twice since 2025-11-06, most recently on 2026-02-25. Since 2024-08-26 it has 10 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -69.0% |
| All-time low | its lowest closing price on record is $1.95 (set on 2022-09-23) | $1.95 |
| Above the all-time low | it is 3204.1% above its all-time low | +3,204% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $3.73 between its high and its low — about 5.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $3.73 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $34.32 and $67.62 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $34.32 – $50.97 – $67.62 |
| Typical daily range (% of price) | its price moves about 5.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.8% |
| Stretch from the 200-day average | it is trading 10.3 daily ranges above its 200-day average price (146.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 10.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.22× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 29.7% since the prior reading | +29.7% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-24 0.8% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.8% |
|---|---|---|
| Open gap | it gapped 34.6% above the previous close 6 sessions ago and has not traded back through the level it left behind at 40.8 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +34.6% |
| Gap filled | a 3.0% gap up opened on 2026-08-06 has been "filled" 12 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 12 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +7.54% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 48.0 percentage points (the stock gained 51.3% while the market gained 3.3%) | +48.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 95.3 percentage points (the stock gained 97.7% while the market gained 2.4%) | +95.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 241.4 percentage points (the stock gained 252.5% while the market gained 11.1%) | +241.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 254.1 percentage points (the stock gained 272.4% while the market gained 18.3%) | +254.1% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 73% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 6.7% of the share price. | +72.9% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 96% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $32.87 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +96.0% |
|---|
Price levels it has turned at before
ETON last closed at $64.43 on 2026-08-24. Since 2024-08-26 it has turned at 10 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $20.01 | Support | 69.0% below the last close | turned there twice · 2025-11-06 to 2026-02-25 |
| $18.36 | Support | 71.5% below the last close | turned there twice · 2025-02-05 to 2025-09-05 |
| $17.54 | Support | 72.8% below the last close | turned there twice · 2025-08-11 to 2025-10-14 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes below $40.61.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $48.00 and $59.96 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 5 trading days, since 2026-08-18.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Overbought (14-day RSI above 70) · Near the 52-week high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Analyst price target recently RAISED | Learn: moving average · golden cross · adx · rsi · macd · breakout · all time high
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$71.00 range $68.00 – $76.00; median $70.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ETON
- Consensus EPS estimate$0.37 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on successful commercialization of rare disease product portfolio and late-stage candidates.","Exposure to regulatory and FDA approval processes, including potential changes to orphan drug fee exemptions.","Risks associated with the integration of acquired pharmaceutical assets and rights."]
What changed in the latest 10-Q
AI-assisted comparison of ETON's 10-Q filed 2026-05-14 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Added HEMANGEOL® and DESMODA™ to list of ten commercial rare disease products (newer filing, 2026-05-14)
- Added disclosure of $14,000 payment for acquisition of U.S. commercial rights to HEMANGEOL® in February 2026 (newer filing, 2026-05-14)
- Added disclosure of $1,000 upfront payment for licensing of U.S. marketing rights to an ultra-rare disease product candidate in February 2026 (newer filing, 2026-05-14)
- Added disclosure that Company no longer qualifies for orphan fee exemption affecting FDA fees (newer filing, 2026-05-14)
- Added specific cash flow table for three months ended March 31, 2026 vs 2025 (newer filing, 2026-05-14)
- Removed:
- Removed ET-600 from list of product candidates in late-stage development (older filing, 2025-11-06, listed five candidates; newer filing lists four)
- Removed nine-month period comparisons and analysis (older filing, 2025-11-06 included nine-month data; newer filing shows only three-month data)
- Removed reference to nine-month cash flow data (older filing, 2025-11-06 included nine-month cash flows; newer filing shows only three-month)
- Removed disclosure about PKU GOLIKE® acquisition payment from March 2024 (no longer relevant in newer period)
- Reworded:
- Updated 10-K reference from 'year ended December 31, 2024 filed...March 18, 2025 (the "2024 10-K")' to 'year ended December 31, 2025 filed...March 19, 2026 (the "2025 10-K")' (newer filing, 2026-05-14)
- Updated Risk Factors reference from 'Part I, Item 1A of our 2024 10-K' to 'Part I, Item 1A of our 2025 10-K' (newer filing, 2026-05-14)
- Changed commercial products count from 'eight' to 'ten' (newer filing, 2026-05-14)
- Changed product candidates count from 'five' to 'four' (newer filing, 2026-05-14)
- Expanded R&D expense explanation to include 'KHINDIVI™ label expansion' (newer filing, 2026-05-14)
- Added reason for G&A increase: 'higher FDA fees as the Company no longer qualifies for the orphan fee exemption' (newer filing, 2026-05-14)
- Changed cash flow period from nine months to three months ended March 31 (newer filing, 2026-05-14)
- Notes:
- The two filings cover different reporting periods (three months ended March 31, 2026 vs. nine months ended September 30, 2025), making some comparisons less directly comparable
- The newer filing's MD&A section appears truncated at the end (ends mid-table with 'GAAP Net income (lo'), which may affect completeness of comparison for later sections
Risk Factors
- Added:
- Exhibit 10.1: Asset Purchase Agreement dated February 27, 2026 by and among Pierre Fabre Medicament Sas and the Registrant (added in 2026-05-14 filing)
- Reworded:
- Reference to '2024 10-K' in older filing (2025-11-06) changed to '2025 10-K' in newer filing (2026-05-14)
- Three-month period ended date changed from 'September 30, 2025' to 'March 31, 2026' in Rule 10b-5 Trading Plans section
- Period ended date in Exhibit 101 changed from 'September 30, 2025' to 'March 31, 2026'
- Condensed Balance Sheets (plural) in newer filing versus Condensed Balance Sheet (singular) in older filing in Exhibit 101 description
- Signature date changed from 'November 6, 2025' to 'May 14, 2026'
- Notes:
- The core Risk Factors Item 1A text is substantively identical between filings except for the 10-K year reference update
- Changes are primarily procedural updates reflecting the different quarterly reporting periods and new exhibit additions
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 10 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 10 sells ($9M) — 2 selling insiders
- Last 180 days0 buys · 17 sells ($16M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-14. As of 2026-08-26.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ETON's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ETON as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 2,564,056
- Reported value $63,280,892
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ETON had 1,313,359 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ETON had 4.59% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.07 days to cover at the same settlement.
- Reported short interest (shares) 1,313,359
- Short interest (% of shares outstanding) 4.59%
- Prior settlement (shares) 1,226,286
- Reported change 7.1%
- Days to cover (reported) 2.07
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Horizon Therapeutics (Amgen)
- BioMarin Pharmaceutical (BMRN)
- Sarepta Therapeutics (SRPT)
- Alexion Pharmaceuticals (AstraZeneca)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ETON vs…
ETON PHARMACEUTCIALS INC is found in…
ETON ranks in…
Frequently asked questions
What does ETON PHARMACEUTCIALS INC (ETON) do?
Eton Pharmaceuticals is an innovative pharmaceutical company focused on the development and commercialization of treatments for rare diseases. The company maintains a portfolio of commercial rare disease products and several candidates in late-stage development. Its business model involves acquiring and commercializing specialty pharmaceutical assets.
What sector is ETON PHARMACEUTCIALS INC (ETON) in?
ETON PHARMACEUTCIALS INC (ETON) is classified in the Health Care sector. Its industry is Specialty Pharmaceuticals. It trades on NASDAQ.
Who are ETON PHARMACEUTCIALS INC's (ETON) competitors?
Notable peers of ETON PHARMACEUTCIALS INC (ETON) include Horizon Therapeutics (Amgen), BioMarin Pharmaceutical, Sarepta Therapeutics and Alexion Pharmaceuticals (AstraZeneca). This peer set is informational only — not financial advice.
Is ETON PHARMACEUTCIALS INC (ETON) overbought or oversold right now?
ETON PHARMACEUTCIALS INC (ETON) is currently in overbought territory (its 14-day RSI is 74, above 70) (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ETON come from?
Fundamentals and prices come from market data, as of 2026-08-26; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-26. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.